Nature Communications 7: Article number: 11815 ; DOI: 10.1038/ncomms11815 (2016); Published June 10 2016; Updated November 14 2016
Previous work by Del Re et al. describing the emergence of KRAS mutations following treatment of non-small cell lung cancer patients with EGFR tyrosine kinase inhibitors was inadvertently omitted from the reference list of this Article and should have been cited as follows. The statement in the Results section ‘While it is well established that KRAS activation is a mechanism of acquired resistance in colorectal cancer patients treated with EGFR-targeting monoclonal antibodies (mAbs)25,26,31,32, this is to our knowledge the first report of EGFR mutant NSCLC patients acquiring activating mutations in KRAS following treatment with an EGFR TKI10,11,23', and the identical statement in the Discussion section, should both have read ‘While it is well established that KRAS activation is a mechanism of acquired resistance in colorectal cancer patients treated with EGFR-targeting monoclonal antibodies (mAbs)25,26,31,32, here we show that EGFR mutant NSCLC patients can also acquire activating mutations in KRAS following treatment with a third generation EGFR TKI. The acquisition of KRAS mutations in EGFR mutant NSCLC patients following treatment with first line EGFR TKIs has recently been reported (Del Re et al.), although these mutations have not been detected in other similar first line cohorts10,11,23,24'.
Del Re et al. contribution of KRAS mutations and c.2369C>T (p.T790M) EGFR to acquired resistance to EGFR-TKIs in EGFR mutant NSCLC: a study on circulating tumor DNA. Oncotarget doi: 10.18632/oncotarget.6957 (2016)